Press Release: Dupixent sBLA accepted for FDA review for the
treatment of chronic spontaneous urticaria
Dupixent sBLA accepted for FDA review for the
treatment of chronic spontaneous urticaria
- Resubmission includes new pivotal data
which confirm Dupixent significantly reduced itch and hive
activity
- More than 300,000 people in the US
suffer from chronic spontaneous urticaria (CSU) that is
inadequately controlled by antihistamines
- FDA decision expected by April 18,
2025; if approved, Dupixent would be the first targeted therapy for
CSU in a decade
Paris and Tarrytown, NY, November 15,
2024. The US Food and Drug Administration (FDA) has
accepted for review the resubmission of the supplemental biologics
license application (sBLA) for Dupixent (dupilumab) to treat adults
and pediatric patients aged 12 years and older with chronic
spontaneous urticaria (CSU) whose disease is not adequately
controlled with H1 antihistamine treatment. The target action date
for the FDA decision is April 18, 2025.
The resubmitted sBLA is supported by data from the
multi-study LIBERTY-CUPID phase 3 clinical program (Study A, Study
B, and Study C) for Dupixent in CSU. The sBLA adds results from
Study C, which was conducted in patients with uncontrolled CSU who
were on standard-of-care antihistamines. Study C, the second
LIBERTY-CUPID pivotal study in biologic-naïve patients, met its
primary and key secondary endpoints, confirming results seen in the
previous Study A. Results showed Dupixent significantly reduced
itch and urticaria activity (itch and hives).
Safety results in all LIBERTY-CUPID phase 3 studies
were generally consistent with the known safety profile of Dupixent
in its approved indications. Adverse events more commonly observed
with Dupixent (≥5%) compared to placebo were injection site
reactions and COVID-19 infection.
About CSU
CSU is a chronic inflammatory skin disease driven in part by type-2
inflammation, which causes sudden and debilitating hives and
recurring itch. CSU is typically treated with H1 antihistamines,
medicines that target H1 receptors on cells to control symptoms of
urticaria. However, the disease remains uncontrolled despite
antihistamine treatment in many patients, some of whom are left
with limited alternative treatment options. These individuals
continue to experience symptoms that can be debilitating and
significantly impact their quality of life. More than 300,000
people in the US suffer from CSU that is inadequately controlled by
antihistamines.
About Dupixent in CSU
The LIBERTY-CUPID Phase 3 study program evaluating Dupixent for CSU
consists of Study A, Study B, and Study C. Study A and Study C were
conducted in CSU patients who were uncontrolled on standard-of-care
antihistamines while Study B was conducted in CSU patients who were
uncontrolled on standard-of-care antihistamines and refractory or
intolerant to omalizumab.
Dupixent has been approved for CSU in Japan and the
United Arab Emirates (UAE) and is also under regulatory review in
the EU based on earlier study readouts. Outside of Japan and the
UAE, the safety and efficacy of Dupixent for CSU has not been fully
evaluated by any regulatory authority.
About Dupixent
Dupixent (dupilumab) is a fully human monoclonal antibody that
inhibits the signaling of the IL4 and IL13 pathways and is not an
immunosuppressant. The Dupixent development program has shown
significant clinical benefit and a decrease in type-2 inflammation
in phase 3 studies, establishing that IL4 and IL13 are two of the
key and central drivers of type-2 inflammation that play a major
role in multiple related and often co-morbid diseases.
Dupixent has received regulatory approvals in more
than 60 countries in one or more indications including certain
patients with atopic dermatitis, asthma, chronic rhinosinusitis
with nasal polyps, eosinophilic esophagitis, prurigo nodularis,
CSU, and chronic obstructive pulmonary disease in different age
populations. More than 1,000,000 patients are currently being
treated with Dupixent globally.
Dupilumab development program
Dupilumab is being jointly developed by Sanofi and Regeneron under
a global collaboration agreement. To date, dupilumab has been
studied across more than 60 clinical studies involving more than
10,000 patients with various chronic diseases driven in part by
type-2 inflammation.
In addition to the currently approved indications,
Sanofi and Regeneron are studying dupilumab in a broad range of
diseases driven in part by type-2 inflammation or other allergic
processes in phase 3 studies, including chronic pruritus of unknown
origin and bullous pemphigoid. These potential uses of dupilumab
are currently under clinical investigation, and the safety and
efficacy in these conditions have not been fully evaluated by any
regulatory authority.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that
invents, develops and commercializes life-transforming medicines
for people with serious diseases. Founded and led by
physician-scientists, our unique ability to repeatedly and
consistently translate science into medicine has led to numerous
approved treatments and product candidates in development, most of
which were homegrown in our laboratories. Our medicines and
pipeline are designed to help patients with eye diseases, allergic
and inflammatory diseases, cancer, cardiovascular and metabolic
diseases, neurological diseases, hematologic conditions, infectious
diseases, and rare diseases.
Regeneron pushes the boundaries of scientific
discovery and accelerates drug development using our proprietary
technologies, such
as VelociSuite®, which
produces optimized fully human antibodies and new classes of
bispecific antibodies. We are shaping the next frontier of medicine
with data-powered insights from the Regeneron Genetics
Center® and pioneering genetic medicine
platforms, enabling us to identify innovative targets and
complementary approaches to potentially treat or cure diseases.
For more information, please visit
www.Regeneron.com or follow Regeneron on LinkedIn,
Instagram, Facebook or X.
About Sanofi
We are an innovative global healthcare company, driven by one
purpose: we chase the miracles of science to improve people’s
lives. Our team, across the world, is dedicated to transforming the
practice of medicine by working to turn the impossible into the
possible. We provide potentially life-changing treatment options
and life-saving vaccine protection to millions of people globally,
while putting sustainability and social responsibility at the
center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ:
SNY
Sanofi Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 |
sandrine.guendoul@sanofi.com
Evan Berland | + 1 215 432 0234
| evan.berland@sanofi.com
Victor Rouault | + 33 6 70 93 71 40 |
victor.rouault@sanofi.com
Timothy Gilbert | + 1 516 521 2929 |
timothy.gilbert@sanofi.com
Sanofi Investor Relations
Thomas Kudsk Larsen |+ 44 7545 513 693 |
thomas.larsen@sanofi.com
Alizé Kaisserian | + 33 6 47 04 12 11 |
alize.kaisserian@sanofi.com
Arnaud Delépine | + 33 6 73 69 36 93
|arnaud.delepine@sanofi.com
Felix Lauscher | + 1 908 612
7239 | felix.lauscher@sanofi.com
Keita Browne | + 1 781 249 1766 |
keita.browne@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 |
nathalie.pham@sanofi.com
Tarik Elgoutni | + 1 617 710 3587 |
tarik.elgoutni@sanofi.com
Thibaud Châtelet | + 33 6 80 80 89 90 |
thibaud.chatelet@sanofi.com
Regeneron Media Relations
Ilana Yellen | +1 914-330-9618|
ilana.yellen@regeneron.com
Regeneron Investor Relations
Mark Hudson | + 914-847-3482 |
mark.hudson@regeneron.com
Sanofi forward-looking
statements
This press release contains forward-looking statements as defined
in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These statements include projections and
estimates regarding the marketing and other potential of the
product, or regarding potential future revenues from the product.
Forward-looking statements are generally identified by the words
“expects”, “anticipates”, “believes”, “intends”, “estimates”,
“plans” and similar expressions. Although Sanofi’s management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, unexpected regulatory actions or delays, or government
regulation generally, that could affect the availability or
commercial potential of the product, the fact that product may not
be commercially successful, the uncertainties inherent in research
and development, including future clinical data and analysis of
existing clinical data relating to the product, including post
marketing, unexpected safety, quality or manufacturing issues,
competition in general, risks associated with intellectual property
and any related future litigation and the ultimate outcome of such
litigation, and volatile economic and market conditions, and the
impact that pandemics or other global crises may have on us, our
customers, suppliers, vendors, and other business partners, and the
financial condition of any one of them, as well as on our employees
and on the global economy as a whole. The risks and uncertainties
also include the uncertainties discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including
those listed under “Risk Factors” and “Cautionary Statement
Regarding Forward-Looking Statements” in Sanofi’s annual report on
Form 20-F for the year ended December 31, 2023. Other than as
required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
All trademarks mentioned in this press release
are the property of the Sanofi group apart from VelociSuite and
Regeneron Genetics Center.
Regeneron Forward-Looking Statements and
Use of Digital Media
This press release includes forward-looking statements that involve
risks and uncertainties relating to future events and the future
performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the
“Company”), and actual events or results may differ materially from
these forward-looking statements. Words such as “anticipate,”
“expect,” “intend,” “plan,” “believe,” “seek,” “estimate,”
variations of such words, and similar expressions are intended to
identify such forward-looking statements, although not all
forward-looking statements contain these identifying words. These
statements concern, and these risks and uncertainties include,
among others, the nature, timing, and possible success and
therapeutic applications of products marketed or otherwise
commercialized by Regeneron and/or its collaborators or licensees
(collectively, “Regeneron’s Products”) and product candidates being
developed by Regeneron and/or its collaborators or licensees
(collectively, “Regeneron’s Product Candidates”) and research and
clinical programs now underway or planned, including without
limitation Dupixent® (dupilumab); the likelihood,
timing, and scope of possible regulatory approval and commercial
launch of Regeneron’s Product Candidates and new indications for
Regeneron’s Products, such as Dupixent for the treatment of chronic
spontaneous urticaria (“CSU”) in the United States as discussed in
this press release as well as the treatment of chronic pruritus of
unknown origin, bullous pemphigoid, and other potential
indications; uncertainty of the utilization, market acceptance, and
commercial success of Regeneron’s Products and Regeneron’s Product
Candidates and the impact of studies (whether conducted by
Regeneron or others and whether mandated or voluntary), including
the studies discussed or referenced in this press release, on any
of the foregoing or any potential regulatory approval of
Regeneron’s Products (such as Dupixent for the treatment of CSU in
the United States) and Regeneron’s Product Candidates; whether the
results from the LIBERTY-CUPID Phase 3 clinical program discussed
in this press release will be sufficient for the U.S. Food and Drug
Administration to approve the resubmitted supplemental biologics
application for Dupixent in CSU; the ability of Regeneron’s
collaborators, licensees, suppliers, or other third parties (as
applicable) to perform manufacturing, filling, finishing,
packaging, labeling, distribution, and other steps related to
Regeneron’s Products and Regeneron’s Product Candidates; the
ability of Regeneron to manage supply chains for multiple products
and product candidates; safety issues resulting from the
administration of Regeneron’s Products (such as Dupixent) and
Regeneron’s Product Candidates in patients, including serious
complications or side effects in connection with the use of
Regeneron’s Products and Regeneron’s Product Candidates in clinical
trials; determinations by regulatory and administrative
governmental authorities which may delay or restrict Regeneron’s
ability to continue to develop or commercialize Regeneron’s
Products and Regeneron’s Product Candidates; ongoing regulatory
obligations and oversight impacting Regeneron’s Products, research
and clinical programs, and business, including those relating to
patient privacy; the availability and extent of reimbursement of
Regeneron’s Products from third-party payers, including private
payer healthcare and insurance programs, health maintenance
organizations, pharmacy benefit management companies, and
government programs such as Medicare and Medicaid; coverage and
reimbursement determinations by such payers and new policies and
procedures adopted by such payers; competing drugs and product
candidates that may be superior to, or more cost effective than,
Regeneron’s Products and Regeneron’s Product Candidates (including
biosimilar versions of Regeneron’s Products); the extent to which
the results from the research and development programs conducted by
Regeneron and/or its collaborators or licensees may be replicated
in other studies and/or lead to advancement of product candidates
to clinical trials, therapeutic applications, or regulatory
approval; unanticipated expenses; the costs of developing,
producing, and selling products; the ability of Regeneron to meet
any of its financial projections or guidance and changes to the
assumptions underlying those projections or guidance; the potential
for any license, collaboration, or supply agreement, including
Regeneron’s agreements with Sanofi and Bayer (or their respective
affiliated companies, as applicable) to be cancelled or terminated;
the impact of public health outbreaks, epidemics, or pandemics
(such as the COVID-19 pandemic) on Regeneron's business; and risks
associated with intellectual property of other parties and pending
or future litigation relating thereto (including without limitation
the patent litigation and other related proceedings relating to
EYLEA® (aflibercept) Injection), other litigation and
other proceedings and government investigations relating to the
Company and/or its operations (including the pending civil
proceedings initiated or joined by the U.S. Department of Justice
and the U.S. Attorney's Office for the District of Massachusetts),
the ultimate outcome of any such proceedings and investigations,
and the impact any of the foregoing may have on Regeneron’s
business, prospects, operating results, and financial condition. A
more complete description of these and other material risks can be
found in Regeneron’s filings with the U.S. Securities and Exchange
Commission, including its Form 10-K for the year ended December 31,
2023 and its Form 10-Q for the quarterly period ended September 30,
2024. Any forward-looking statements are made based on management’s
current beliefs and judgment, and the reader is cautioned not to
rely on any forward-looking statements made by Regeneron. Regeneron
does not undertake any obligation to update (publicly or otherwise)
any forward-looking statement, including without limitation any
financial projection or guidance, whether as a result of new
information, future events, or otherwise.
Regeneron uses its media and investor relations
website and social media outlets to publish important information
about the Company, including information that may be deemed
material to investors. Financial and other information about
Regeneron is routinely posted and is accessible on Regeneron's
media and investor relations website
(https://investor.regeneron.com) and its LinkedIn page
(https://www.linkedin.com/company/regeneron-pharmaceuticals).
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
